Downloadable BluePrint resource on PCSK9 inhibitor therapies in ACS
Early (in-hospital) initiation of PCSK9 inhibitor therapy in patients with acute coronary syndrome may provide additional clinical benefit when used on top of statin treatment. This BluePrint describes current recommendations regarding low-density lipoprotein cholesterol targets in patients with ACS, the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the rationale for its inhibition in ACS, and the expected clinical impact of PCSK9 inhibitors in the acute phase of ACS.
The BluePrint was developed by CORONARY CONNECT members Prof. Uwe Zeymer, Prof. Zuzana Motovska, Prof. Anna Franzone, Prof. Jeanine Roeters van Lennep, and Dr. Flavien Vincent and is available now for download.
You can explore more CORONARY CONNECT programmes using the button below.
Development of this BluePrint was supported by an Independent Educational Grant from Amgen